Knowing that a sample contains IGF-related material is not the same as identifying the intended intact analogue. This analytical study examined that distinction. Primary study
What was studied
Researchers combined antibody-based purification with high-resolution mass spectrometry. Validation used spiked human serum, while administration experiments involved rats; human whole blood was also examined outside the body. Oxidized forms and breakdown products were detected, including in sampled nonregulated products. This was not a human pharmacokinetic trial. Primary report
Our appraisal: detection depends on what the assay seeks
An assay aimed only at the unchanged molecule may answer a different question from one that also identifies modified forms. A missing parent signal does not establish that all related material has disappeared. Conversely, a fragment signal does not show that the intact compound remains biologically active.
Validation terms have distinct meanings. Recovery concerns how much of an analyte survives preparation; specificity concerns distinguishing it from other signals; matrix effects concern interference from the sample environment. None alone establishes the entire method's suitability. A useful assay account should show these components rather than quoting only its most sensitive detection limit.
Species and setting also constrain interpretation. Spiking a human sample tests analytical performance in that matrix, not distribution and elimination in a living person. Whole-blood incubation adds a biological degradation setting, but it still lacks organs, circulation and clearance. Rat administration data cannot simply supply a human half-life or a universal detection window.
Finally, evidence of modified material in sampled products is not a batch certificate for any other seller. Product-specific conclusions require traceable sampling and testing of the actual lot. This paper supports careful molecular identification; it does not establish the identity, purity, sterility or clinical suitability of an untested product.
Frequently asked questions
Was this an efficacy trial?
No; it was analytical research.
Were human volunteers administered the analogues?
Not in this study.
Were modified peptide forms considered?
Yes.
Is detection limit the same as half-life?
No.
Does a fragment prove intact peptide activity?
No.
Does serum validation establish human pharmacokinetics?
No.
Can the paper certify a catalog batch?
No; batch-specific evidence is required.